You are here

Drug developer Cennerv lodges prospectus for Catalist IPO

It specialises in treatments for depression, insomnia, dementia and autism

Singapore

SINGAPORE-based biotech Cennerv Pharmaceuticals, a developer of drugs to treat central nervous system (CNS) disorders, lodged a preliminary prospectus on Wednesday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist

sentifi.com

Market voices on: